An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 in patients with selected advanced and/or metastatic solid tumours (colorectal cancer, ovarian cancer, pancreatic cancer or renal cell carcinoma)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510836-31-00

Acronym

OATD-02-C-01

Enrollment

Registered

2024-04-12

Start date

2023-02-14

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced and/or metastatic solid tumours (colorectal cancer, ovarian cancer, pancreatic cancer or renal cell carcinoma)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026